⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1025428 | 0.97 | — | — | |
| Acetic Acid SCHEMBL1221543 | 0.87 | ALDH1A1 (0.48) | — | |
| SCHEMBL12569640 | 0.78 | — | — | |
| SCHEMBL10425678 | 0.78 | — | — | |
| SCHEMBL10425679 | 0.78 | — | — | |
| SCHEMBL20404218 | 0.75 | — | — | |
| SCHEMBL293738 | 0.75 | — | — | |
| SCHEMBL28388543 | 0.75 | NOS3 (0.33) | — | |
| SCHEMBL8297109 | 0.73 | — | — | |
| SCHEMBL6373931 | 0.73 | NOS3 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11076600-B2 | Mixtures of cis-jasmone and bacillus amyloliquefaciens | BASF SE (DE) | 2021-08-03 | — | — | US | claimed |
| CN-109068645-A | Mixtures and compositions comprising a paenibacillus strain or fusaricidin and a chemical pesticide | 巴斯夫欧洲公司 | 2018-12-21 | — | — | CN | claimed |
| US-20180317498-A1 | Mixtures of Cis-Jasmone and Bacillus Amyloliquefaciens | BASF SE (DE) | 2018-11-08 | — | — | US | claimed |
| CN-104529904-B | The preparation method of Bo Maxini | 苏州明锐医药科技有限公司 | 2016-08-31 | — | — | CN | claimed |
| CN-104529904-A | Preparing method for bemaciclib | SUZHOU MIRACPHARMA TECHNOLOGY CO LTD | 2015-04-22 | — | — | CN | claimed |
| US-7553850-B2 | Tricyclic-bridged piperidinylidene derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA NV (BG) | 2009-06-30 | — | — | US | claimed |
| EP-1910353-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007030089-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-15 | — | — | WO | claimed |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-09 | — | — | US | claimed |
| EP-0385038-B1 | ORTHO-SUBSTITUTED PHENYL AMIDINE AND PHENYL GUANIDINE DERIVATIVES AND ANTIDIABETIC OR HYPOGLYCAEMIC AGENTS CONTAINING THEM | The Boots Company PLC (GB) | 1993-06-02 | — | — | EP | claimed |
| EP-0385038-A1 | Ortho-substituted phenyl amidine and phenyl guanidine derivatives and antidiabetic or hypoglycaemic agents containing them | The Boots Company PLC (GB) | 1990-09-05 | — | — | EP | claimed |
| WO-2024119067-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | Neumora Therapeutics, Inc. (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2024039901-A2 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024039903-A2 | CDK2 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-4259482-A | NON-SPECIFIC DEPRESSION OF CENTRAL NERVOUS SYSTEM | MEAD JOHNSON & COMPANY (US) | 1981-03-31 | — | — | US | disclosed |
| US-4206142-A | REACTING A STYRYLSULFONYLAMIDINE WITH A BASE | MEAD JOHNSON & COMPANY (US) | 1980-06-03 | — | — | US | disclosed |
| US-4130663-A | ANTITHROMBOGENIC, ANTIHYPERTENSIVE | MEAD JOHNSON & COMPANY (US) | 1978-12-19 | — | — | US | disclosed |
| US-4096183-A | Styrylsulfonylamidines | MEAD JOHNSON & COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
| US-4052455-A | ANALGESICS, BLOOD PLATELET AGGREGATION INHIBITORS | MEAD JOHNSON & COMPANY (US) | 1977-10-04 | — | — | US | disclosed |